HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $4 Price Target
BioCardia Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and Femasys (FEMY)
BioCardia's Strategic Clinical Advancements and Potential Growth Opportunities Prompt Buy Rating
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $4 Price Target
BioCardia Analyst Ratings
HC Wainwright Adjusts BioCardia's Price Target to $4 From $9, Keeps Buy Rating
BioCardia Analyst Ratings
H.C. Wainwright Remains a Buy on BioCardia (BCDA)
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $9 Price Target
BioCardia Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for BioCardia (BCDA)
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $9 Price Target
BioCardia Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on BioCardia (BCDA)
H.C. Wainwright Remains a Buy on BioCardia (BCDA)
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $9 Price Target
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $9 Price Target
H.C. Wainwright Sticks to Their Buy Rating for BioCardia (BCDA)
BioCardia (BCDA) Receives a Buy From H.C. Wainwright
No Data